PharmaEssentia Corporation
6446
주식 순위
#1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
주가
$37.84
시가총액
$15.65B
변동 (1일)
-4.42%
변동 (1년)
149.23%
국가
TW
거래 PharmaEssentia Corporation (6446)
카테고리
Healthcare
PharmaEssentia Corporation (6446)의 배당 이력
PharmaEssentia Corporation (주식 심볼: 6446)은 총 1회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): $0.99
배당 수익률 (TTM): 0.0012
모든 배당금의 합계 (주식 분할 반영): $0.99
배당 수익률 (TTM): 0.0012
PharmaEssentia Corporation (6446)의 2025부터 2026까지 배당 지급 내역
연간 배당 지급
| 연도 | 배당금 (주식 분할 조정됨) | 변화 |
|---|---|---|
| 2026 (TTM) | $0.9898 | 0.00% |
| 2025 | $0.9898 | 0.00% |
모든 배당 지급 목록
| 연도 | 배당금 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.10 | 0.00% |
| 2025 | $1.10 | 0.00% |
유사 기업 또는 경쟁사의 배당 지급
| 회사 | 배당 지급 횟수 | 국가 |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 38.00% |
IN
|
